Irinotecan and 5-fluorouracil in colorectal cancer: Time for a pause?

European Journal of Cancer

Volumn 34, Issue 3, 1998, Pages 286-289

  Bulusu, V R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FLUOROURACIL; IRINOTECAN;

CLINICAL TRIAL; COLORECTAL CANCER; DNA DAMAGE; DNA SYNTHESIS; DRUG MECHANISM; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0032005592     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10064-8     Document Type: Article

References (36)

1. 1. Devita Jr VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. Philadelphia, JB Lippincott, 1996.
2. 2. Advanced Colorectal Cancer Meta Analysis Project: modulation of fluorouracil by leukovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Meta Analysis Project. J Clin Oncol 1992, 10, 896-903.
3. 3. Rougier P, Culine S, Bugat R, et al. A phase II study of CPT-11 (irinotecan) in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pre-treated with 5-FU based chemotherapy. J Clin Oncol 1997, 15, 251-260.
4. 4. Conti JA, Kemeny NE, Salts LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14, 709-715.
5. 5. Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995, 31A, 1283-1287.
6. 6. Rothenberg ML, Eckardt JR, Burris III HA, et al. Irinotecan (CPT-11) as second line therapy for patients with 5FU-refractory colorectal cancer. 30th Annual Meeting of the American Society of Clinical Oncology, 14-17 May 1994, Dallas, Texas, abstract 578.
7. 7. Shimada M, Yashino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993, 11, 909-913.
8. 8. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246, 1046-1048.
9. 9. Hirabayashi N, Kim R, Nishiyama M, et al. Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues. Proc Am Assoc Cancer Res 1992, 33, 436.
10. 10. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 1992, 50, 604-610.
11. 11. Matsuoka-H, Yano K, Takiguchi S, et al. Advantge of combined treatment with CPT-II and 5-fluorouracil. Anti Cancer Res 1995, 15, 1447-1452.
12. 12. Akutsu M, Suzuki K, Tsunoda S, et al. Effects of SN-38 in combination with other anticancer agents against Dauji cells. Gan-To-Kagaku-Ryoho 1994, 21, 1607-1611.
13. 13. Allegra CJ, Grem JL. Antimetabolites. In Devita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, JB Lippincott, 1996, pp. 432-452.
14. 14. Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260, 14873-14878.
15. 15. Liu LF. DNA topoisomerase poisons as anticancer drugs. Annu Rev Biochem 1989, 58, 351-375.
16. 16. Avemann K, Knippers R, Koller T, Sogo JM. Camptothecin, a specific inhibitor of type I DNA topoisomerase induces DNA breakage at replication forks. Mol Cell Biol 1988, 8, 3026-3034.
17. 17. Ryan AJ, Squires S, Strutt HL, Johnson RT. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acid Res 1991, 19, 3295-3300.
18. 18. Pommier Y, Leteurtre F, Fesen M, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994, 12, 530-542.
19. 19. D'Arpa P, Beardsmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990, 50, 6919-6924.
20. 20. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerases I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989, 49, 6365-6368.
21. 21. Ryan AJ, Squires S, Strutt HL, et al. Different rates of camptothecin induced replication fork associated double-strand breaks in mammalian cells. Carcinogenesis 1994, 15, 823-828.
22. 22. Tsao YP, D'Arpa P, Liu LF. The involvement of active DNA synthesis in camptothecin induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 1992, 52, 1823-1829.
23. 23. Pinero J, Lopez-Baena M, Ortiz T, Cortes F. Sister chromatid exchange induced by DNA topoisomerase poisons in late replicating heterochromatin. Influence of inhibition of replication and transcription. Mutat Res 1996, 354, 195-201.
24. 24. Zhang H, Wang JC, Liu LF. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci USA 1988, 85, 1060-1064.
25. 25. Del Bino G, Lassota P, Darzynkiewicz Z. The S phase cytotoxicity of camptothecin. Exp Cell Res 1991, 193, 27-35.
26. 26. Seimiya-H, Mashima-T, Toho M, et al. C-Jun NH2-terminal-kinase mediated activation of interleukin-1-beta converting enzyme/CED-3-like protease during anti cancer drug induced apoptosis. J Biol Chem 1997, 272, 4631-4636.
27. 27. Okamoto S, Sakai M, Uchida J, et al. 5-Fluorouracil induced apoptotic cell death with G2 phase arrest in human breast cancer grafted in nude mice. Anti Cancer Res 1996, 16, 2699-2704.
28. 28. Shimada Y, Sasaki Y, Sugano K, et al. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1993, 12, 196, abstract 575.
29. 29. Saltz LB, Kanowitz J, Kemeny NE, et al. Phase I clinical and pharmaco kinetic study of irinotecan (CPT-11), 5-fluorouracil and leucovorin in patients with advanced solid tumours. J Clin Oncol 1996, 14, 2959-2967.
30. 30. Grossin F, Barbault H, Benhammoud A, et al. A phase I pharmacokinetic study of concomitant CPT-11(C) and 5FU(F) combination. Annual Meeting of the American Association of Cancer Research (AACR), 23 April 1996, Washington, USA.
31. 31. Saltz L, Shimada Y, Khayat D. CPT-11 (irinotecan) and 5-fluorouracil; a promising combination therapy for colorectal cancer. Eur J Cancer 1996, 32A, S24-S31.
32. 32. Benhammouda A, Bastian G, Rixe O, et al. A phase I and pharmacokinetic (PK) study of CPT-11 (C) and 5-FU (F) combination. Proc Am Soc Clin Oncol 1997, 16, abstract 710.
33. 33. Ducreux M, Rougier P, Ychou M, et al. Phase I/II study of escalating dose of CPT-11 in combination with LV5-FU2 (DeGramont' regimen) every two weeks in the treatment of colorectal cancer (CRC) after 5-FU failure. Proc Am Soc Clin Oncol 1997, 16, abstract 823.
34. 34. Paz-Ares L, Sastre J, Diaz-Rubio E, et al. Phase I dose-finding study of irinotecan (CPT-11) over a short infusion combined with a fixed dose of 5-fluorouracil (5-FU) protracted continuous i.v. infusion in patients with advanced solid tumours. Proc Am Soc Clin Oncol 1997, 16, abstract 874.
35. 35. Rothenberg ML, Pazdur R, Rowinsky EK, et al. A phase II multicentre trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously treated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1997, 16, abstract 944.
36. 36. Barone C, Pozzo V, Starkhammar H, et al. CTP-11 alternating with 5-fluorouracil (5-FU) folinic acid (FA): a multicentre phase II study in first line chemotherapy (CT) of metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1997, 16, abstract 957.